TSOI Expanding Frontiers of Stem Cell Treatments

In today's episode, Dr. Veltmeyer discusses the recent successes of Therapeutic Solutions International in the area of adult stem cell research, leading to potential treatments for COVID-19 and Chronic Traumatic Encephalopathy ( CTE ). TSOI's patented universal donor adult stem cell product known as JadiCell has shown significant reduction of lung injury based on preservation of lung function, reduction of inflammatory cells entering the lung, and suppression of specific proteins such as C5a which are associated with poor prognosis in COVID-19 patients. In an FDA double-blind placebo-controlled clinical trial, the JadiCell was successful at substantially improving survival in end-stage patients with COVID-19 associated acute lung failure. Specifically, treatment was associated with significantly improved patient survival ( 91% versus 42% ) of individuals over the age of 85. JadiCell was actually shown to be 100% effective in saving the lives of COVID patients under the age of 85.

In addition, TSOI’s research is indicating the superior ability of JadiCell in stimulating production of new brain cells. This process is called “neurogenesis” and has great potential in the fight against Alzheimer’s Disease, Parkinson’s Disease, and various forms of dementia.